CorVel Corp. (CRVL) Stock Price & How to Invest

CorVel Corporation is a Nasdaq-listed provider of workers' compensation claims management and healthcare cost-containment services. It runs two reporting segments: Patient Management, which handles third-party claims administration, case management, and return-to-work services for self-insured employers and carriers, and Network Solutions, which covers medical bill review, PPO network access, pharmacy management, and, through the CERIS brand, payment integrity for commercial health payers. The company layers artificial intelligence, machine learning, and natural language processing over its proprietary CareMC platform (recently extended with a tool called CorVel Connected) to flag billing errors, route care, and compress the cost of an episode.

The investment picture is a compounder that lost its premium multiple and is now earning part of it back. Fiscal 2026 (ended March 31, 2026) revenue rose ~7% to ~$959 million and diluted EPS rose ~17% to ~$2.14, with operating margin expanding about 1.4 points to ~14.9%. The stock fell from a 2025 high near ~$94 to the mid-$40s at its low, because the market repriced growth: 7% top-line expansion was well below what CorVel's historical multiple assumed, and workers' compensation claim frequency has been declining for years as workplaces get safer and insurers cut rates. The fiscal first quarter of 2027 (ended June 30, 2026), reported August 5, changed the tone: revenue rose 11% to about $259.9 million, gross margin widened to about 26%, net income rose about 18% to $32.2 million, and diluted EPS rose 21% to $0.63, helped by a shrinking share count after $21.8 million of buybacks. CorVel ended the quarter with about $256 million of cash and no borrowings. In September 2026 it released a CareMC extension for Guidewire ClaimCenter, plugging its managed-care tools into a widely used insurer claims system. The shares closed at $80.33 on October 16, 2026, up about 22% year to date and 14% over one year, and the fiscal second-quarter report is scheduled for November 3, 2026. The bull framing rests on CERIS and payment integrity broadening the addressable market beyond workers' compensation; the bear framing is that a services business without a dividend, now back near 36 times earnings, has little room for another slowdown.

The core end market is the central risk: workers' compensation claim frequency has trended down for years as workplaces automate and get safer, and soft premium rates squeeze what carriers and employers will pay for managed-care services. The stock's swing, from a 2025 high near $94 down to about $45 within the past year and back to about $80, shows how quickly the multiple moves on growth expectations; at about 36 times trailing earnings, a return to mid-single-digit growth could compress it again. Competition is intense and much better capitalized, with Sedgwick, Enlyte, Gallagher Bassett, and Optum's workers' compensation units all bidding on overlapping mandates. CorVel is also early in a leadership transition, with Sarah Scott stepping in as CEO and President effective July 1, 2026 and prior CEO Michael Combs moving to Executive Chair. Coverage is thin, with little published analyst consensus, so estimates offer less of an anchor than for larger names. Finally, the CERIS payment-integrity expansion puts CorVel into commercial health, where entrenched specialists such as Optum, Cotiviti, and Zelis already hold scale relationships.

We give no verdict on CorVel Corp.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. CERIS and commercial payment integrity. CERIS, CorVel's payment-integrity arm, targets commercial health payers rather than the workers' compensation pool, which is the company's main route to a larger addressable market.

The case against. The core end market is the central risk: workers' compensation claim frequency has trended down for years as workplaces automate and get safer, and soft premium rates squeeze what carriers and employers will pay for managed-care services.

Read the full bull and bear case on CRVL, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. CorVel Corp. (CRVL) has had one share split in the last 10 years:

• 3:1 on December 26, 2024, so every share held became 3 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of CRVL the day before the 3:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CorVel Corp.'s investor relations page or your broker.

• Revenue (TTM to Jun 30, 2026): ~$984M; FQ1 2027 ~$260M (+11% YoY)
• Diluted EPS (TTM / FQ1 2027): ~$2.24 / $0.63 (+21% YoY)
• Net income (TTM): ~$115M; FQ1 2027 ~$32.2M (+18% YoY)
• Operating margin (TTM): ~16.7% (FY2026 ~14.9%)
• Cash and debt (Jun 30, 2026): ~$256M cash, no borrowings
• Market cap / trailing P/E: ~$4.1B / ~36x at $80.33 (Oct 16, 2026)

CorVel's fiscal year ends March 31, so the trailing figures run through the June 2026 quarter, with fiscal Q2 2027 due November 3, 2026. The trailing P/E near 36 is well above the ~28 the stock carried in mid-2026, after shares rose about 34% in three months on re-accelerating growth, though still below the premium it held through 2025. The 52-week range of roughly $45 to $83 shows how far sentiment has swung while earnings kept growing.

Other names that sit close to CRVL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CRVL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRVL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRVL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CorVel is a quietly profitable niche compounder whose valuation reset early in 2026 and then recovered much of the way, back to about 36 times trailing earnings, and the debate is whether CERIS and payment integrity can outgrow a slow-fading workers' compensation core.

Whether CRVL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRVL a buy or a sell?, and where the stock could go from here in the CRVL stock forecast.

For income investors, whether CRVL pays a dividend and how the payout looks is covered in does CRVL pay a dividend? And to weigh CRVL against a peer, read the full side-by-side comparisons: CRVL vs AJG.